人抗HBsAg噬菌体抗体Fab段基因的序列分析及表达

对已建的噬菌体抗体库分离出来的人抗－ＨＢｓ克隆进行了序列分析和表达研究，发现４个克隆中３个克隆的重链和轻链完全相同，ＤＮＡ序列分析表明ＶＨ分别属于ＶＨ１亚群和Ⅱ亚群，其轻链ＶＬ分别属于ＶλⅡ亚群和ＶλⅠ亚群。构建了可溶性Ｆａｂ段表达载体，显示出在细菌中表达的Ｆａｂ段抗体与ＨＢｓＡｇ特异性结合，这说明所筛选出来的噬菌体抗体具有ＨＢdisplay status     

延边地区各种肝病患者HBsAg携带者及单项ALT增高者中抗-HCV分布

自1991年11月到1992年2月,用酶联免疫吸附试验对延边地区87例各种肝病患者.65例HBsAg携带者及5例单项ALT增高者血清共157份进行了抗-HCV检测.33例呈阳性,总阳性率为21.0％,其中单项ALT增高者高达80.O％.其次.急性肝炎为35.2％.慢性迁延性肝炎为18.2％.HBsAg携带者为6.2％,肝硬化为0％.     

检测各型乙肝患者血小板功能的临床意义

检测198例各型乙肝患者血小板功能的五个项目：血小板总数、粘附试验、聚集试验、血块退缩、血小板第3因子有效性，发现各期乙肝患者血小板功能的异常有显著性差异（P＜0．01）．并提示乙肝患者除有血小板数量的改变外，还有质量的改变，因此，全面的血小板功能检测可作为估计乙肝患者肝损害程度的辅助指标．     

丙型肝炎患者PBMC的mIL-2R表达及其临床意义

目的 探讨丙型肝炎患mIL-2R表达水平及其临床意义。方法 用生物素-链酶亲和素法对56例抗-HCV阳性患外周血单个核细胞(PBMC)进行植物血凝素(PHA)诱导前后mIL-2R的的检测。结果 急、慢性丙型肝炎患静息状态mIL-2R表达水平，诱导状态mIL-2R表达水平分别与正常对照相比，差异均有显性。结论 丙型肝炎患体内存在明显的细胞免疫功能紊乱，T细胞活化障碍，并与肝病的慢性化有关。     

A model to predict long-term sustained response to interferon therapy in chronic hepatitis C

Interferon therapy is used widely for chronic hepatitis C but only a minority of treated patients achieve a long-lasting sustained response. We have developed, by logistic regression, a mathematical model to estimate the probability of sustained response in an individual patient with chronic hepatitis C when treated with interferon-α (IFN-α). The model, which includes age, sex, disease duration, pretreatment serum γ-glutamyl-transpeptidase, alanine aminotransferase and virus genotype, was developed from a database of 307 patients and validated in a new set of 200 patients. It performed well as goodness-of-fit ( P = 0.71 and P = 0.15 in the development and test sample, respectively) and discrimination (area under receiver operating curve = 0.79 in the development and 0.78 in the test sample, respectively). This model may provide decision support in the treatment of chronic hepatitis C with IFN-α.     

单项抗HBc阳性的临床分析

临床上对于乙型肝炎的诊断主要是依据病人的 HBV- M结果进行判断 ,对于单项抗 HBc阳性的临床意义 ,目前有不同的争议。通过在临床工作中搜集整理的有关资料进行总结分析 ,认为单项抗 HBc阳性的意义与其在血清中的滴度有关。     

病毒性心肌炎心肌肌钙蛋白Ⅰ检测的临床意义

目的:对病毒性心肌炎患儿血中肌钙蛋白I(cTn I)含量进行检测,探讨与临床的关系。方法:采用放射免疫法对24例病毒性心肌炎患儿血中cTn I进行定量检测,同时检测血清心肌酶谱的改变情况,并就两种指标进行相关性探讨。结果:病毒性心肌炎患儿血中cTn I含量明显增高(4.5±2.2 )vs(2.3±0.3)ng/ml,P<0.01),并与CKMB,LDH_1的含量呈明显的正相关。结论:cTnl I是诊断病毒性心肌炎的敏感指标,可以反映出心肌受损的程度。     

异烟肼、利福平治疗肺结核致肝毒性易感基因的研究

目的：探讨N-乙酰基转移酶(NAT2)基因型与异烟肼、利福平治疗肺结核致肝毒性的相关性。方法：通过聚合酶链反应-限制性片段长度多态性(PCR—RFLP)技术分析67例经利福平、异烟肼治疗后发生或未发生肝功能异常的肺结核患者NAT2基因多态性的部位、性质及发生率。结果：病例组和对照组857位密码子多态性分别是20．3％和7．1％，两组差异显著。结论：NAT2基因型与异烟肼和利福平所致肝毒性关系密切，其中857位密码子点突变可能是结核患者发生肝毒性的易感基因型之一。     

乙型肝炎病毒多表位治疗性抗原基因的合成、表达及抗原性研究

目的研究乙型肝炎病毒多表位治疗性疫苗基因的合成、表达及其产物的抗原性。方法设计、并合成乙型肝炎病毒多表位抗原基因BPT,克隆入融合表达载体pWR450-1,构建重组质粒PWR/BPT。在大肠杆菌中表达乙型肝炎多表位抗原蛋白并纯化该蛋白,并用Western-blotting方法初步检测该抗原蛋白的抗原性。结果成功构建了融合表达载体PWR/BPT,在大肠杆菌中表达出乙型肝炎多表位抗原蛋白,Western-blotting 检测显示该蛋白具有良好抗原性。结论HBV多表位治疗性抗原基因的设计是成功的,其在大肠杆菌中表达的重组融合蛋白具有良好的抗原性,可能是较理想的HBV治疗性疫苗候选物。     

Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus.

BACKGROUND: Seroreversion, negativation of anti-hepatitis C virus previously positive, is sometimes found in some chronic hepatitis C-sustained responders (SRs) to antiviral therapy. AIMS: To determine the probability of seroreversion in SR treatment with Interferon and Ribavirin, and lymphocyte T helper (CD4+) reactivity to HCV antigens. METHODS: Thirty SR were followed on average for 54.8 months. Anti-HCV was tested by third generation test. Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood and cultured to evaluate CD4+ proliferation in response to 2 microg/ml of eight HCV recombinant antigens from core, NS3, NS4, NS5 regions. RESULTS: Seroreversion was verified in 23% of patients (7/30), appearing at 47.5+/-24.0 months. The probability of anti-HCV loss in this group was 25% at 56 months after ending therapy. In 57% (4/7), anti-HCV returned to positive. These 7 SR patients with seroreversion also showed weaker CD4+ reactivity in 5% of tests (3/56) than the remaining 23 anti-HCV-positive SRs who showed stronger reactivity in 18% of tests (33/184), P=0.036. CONCLUSIONS: One-quarter of the SR showed seroreversion of anti-HCV and weaker CD4+ specific HCV proliferation than those who remained anti-HCV positive. The data suggest that complete viral eradication is a possible and achievable clinical objective.